<?xml version='1.0' encoding='utf-8'?>
<document id="29096571"><sentence text="Elevated Creatine Kinase due to Potential Drug Interaction With Ticagrelor and Atorvastatin."><entity charOffset="9-17" id="DDI-PubMed.29096571.s1.e0" text="Creatine" /><entity charOffset="64-74" id="DDI-PubMed.29096571.s1.e1" text="Ticagrelor" /><entity charOffset="79-91" id="DDI-PubMed.29096571.s1.e2" text="Atorvastatin" /><pair ddi="false" e1="DDI-PubMed.29096571.s1.e0" e2="DDI-PubMed.29096571.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29096571.s1.e0" e2="DDI-PubMed.29096571.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29096571.s1.e0" e2="DDI-PubMed.29096571.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29096571.s1.e1" e2="DDI-PubMed.29096571.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29096571.s1.e1" e2="DDI-PubMed.29096571.s1.e2" /></sentence><sentence text="Ticagrelor and atorvastatin are commonly used medications in the management of acute coronary syndrome and percutaneous intervention"><entity charOffset="0-10" id="DDI-PubMed.29096571.s2.e0" text="Ticagrelor" /><entity charOffset="15-27" id="DDI-PubMed.29096571.s2.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.29096571.s2.e0" e2="DDI-PubMed.29096571.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29096571.s2.e0" e2="DDI-PubMed.29096571.s2.e1" /></sentence><sentence text=" This is a report of a patient case of a potential drug interaction leading to the use of alternative therapy" /><sentence text="" /><sentence text="A 58-year-old male presented for cardiac catheterization following an abnormal stress test" /><sentence text=" He underwent placement of a drug-eluting stent and was started on ticagrelor" /><sentence text=" Three months later, he was noted to have elevated creatine kinase (CK), thought to be related to a potential drug-drug interaction between ticagrelor and atorvastatin"><entity charOffset="51-59" id="DDI-PubMed.29096571.s7.e0" text="creatine" /><entity charOffset="155-167" id="DDI-PubMed.29096571.s7.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.29096571.s7.e0" e2="DDI-PubMed.29096571.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29096571.s7.e0" e2="DDI-PubMed.29096571.s7.e1" /></sentence><sentence text=" Ticagrelor was discontinued and he was successfully transitioned to clopidogrel"><entity charOffset="1-11" id="DDI-PubMed.29096571.s8.e0" text="Ticagrelor" /><entity charOffset="69-80" id="DDI-PubMed.29096571.s8.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.29096571.s8.e0" e2="DDI-PubMed.29096571.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29096571.s8.e0" e2="DDI-PubMed.29096571.s8.e1" /></sentence><sentence text=" CK returned to normal within weeks of this change" /><sentence text="" /><sentence text="Pharmacokinetic studies have demonstrated a potential interaction between ticagrelor and atorvastatin but have not been deemed clinically significant"><entity charOffset="89-101" id="DDI-PubMed.29096571.s11.e0" text="atorvastatin" /></sentence><sentence text=" To date, only one other case report has been published discussing this interaction and consideration of alternative therapy" /><sentence text=" This case report is unique, with ticagrelor being the only new medication added prior to the abnormal CK finding"><entity charOffset="34-44" id="DDI-PubMed.29096571.s13.e0" text="ticagrelor" /></sentence><sentence text="" /><sentence text="A probable drug-drug interaction occurred with concomitant ticagrelor and atorvastatin"><entity charOffset="59-69" id="DDI-PubMed.29096571.s15.e0" text="ticagrelor" /><entity charOffset="74-86" id="DDI-PubMed.29096571.s15.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.29096571.s15.e0" e2="DDI-PubMed.29096571.s15.e0" /><pair ddi="false" e1="DDI-PubMed.29096571.s15.e0" e2="DDI-PubMed.29096571.s15.e1" /></sentence><sentence text=" While this interaction may not always be clinically significant, it is reasonable to consider in patients who present with signs and symptoms of adverse effects" /><sentence text="" /></document>